ClinicalTrials.gg
CompletedNCT07777965Updated Sep 8, 2026

Abuse Potential of Oral Gabapentin in Healthy, Non-Drug-Dependent Individuals With Recreational Sedative Drug Use Experience

A Phase 4 interventional study of Alprazolam (Xanax) and Placebo in Healthy Non-dependent, Recreational Sedative Users, sponsored by Viatris Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Viatris Inc. · Phase 4, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of the present study is to assess prospectively the abuse potential of gabapentin compared to placebo and alprazolam in healthy non-drug-dependent recreational sedative drug users under fasted condition.

Read the detailed description

The study includes Screening, a Qualification Phase consisting of a Naloxone Challenge and Drug Discrimination crossover study, a Treatment Phase and Follow-up. Following successful completion of the Qualification Phase the participants will be enrolled in the Treatment phase. The Treatment Phase is a randomized, double-blind, placebo- and active-controlled, 4 period crossover, single-dose, Williams square design study in healthy male and female adult, non-dependent, recreational sedative users. On Day 1 of each of the Treatment Phase 4 periods, which will be separated by a washout of at least 6 days, participants will receive an oral dose of either gabapentin 1800 mg or 1200 mg or 2 mg alprazolam, or placebo. Study treatments will be administered under fasted conditions (overnight fast and no food until 4 hours after dosing). Water will be allowed without restriction except from 1 hour prior to dosing until 1 hour after dosing.

02

Conditions studied

  • Healthy Non-dependent, Recreational Sedative Users
03

In context

Lead sponsor

Viatris Inc. is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female participants must be 18 to 55 years of age, inclusive, at the time of screening. At least 20% of participants randomized into the Treatment Phase should be female.
  2. Male participants must agree to the following requirements during the intervention period and for at least 93 days after the last dose of study intervention, which corresponds to the time needed to eliminate study intervention(s) plus an additional 90 days (a spermatogenesis cycle):

    • Refrain from donating sperm.

    PLUS either:

    • Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent; OR
    • Must agree to use /barrier as detailed below:
    • Agree to use a male condom and spermicide when engaging in any activity that allows for passage of ejaculate to another person.
    • Male participants should be advised of the benefit for a female partner to use a highly effective method of contraception, as a condom may break or leak when having sexual intercourse with a woman of (WOCBP) who is not currently pregnant.

      - A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least 1 of the following conditions applies:

    • Is not a WOCBP; OR
    • Is a WOCBP and using a contraceptive method
    • A WOCBP agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during the study and for 30 days after the last dose of product. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
  3. Participants who are overtly healthy. Healthy is defined as no abnormalities identified by a detailed medical history, complete physical examination, vital signs, 12-lead (ECG), and/or clinical laboratory tests.
  4. Participants must be recreational sedative drug users, defined as those reporting using a sedative agent (e.g., barbiturates, benzodiazepines) for its intoxicating effects on at least 10 lifetime occasions and at least once in the 12 weeks before the Screening Visit, but who have no signs of dependence and are not seeking treatment for their sedative use.
  5. Participants must satisfactorily complete the Drug Discrimination phase.
  6. (BMI) of 17.5 to 34 kg/m2, inclusive; and a total body weight ≥50 kg (110 lb).

Exclusion criteria

Exclusion Criteria:

  1. Participants with current or past diagnosis of any type of drug dependence within the past year. Diagnosis of substance and/or alcohol dependence (excluding caffeine and nicotine) will be assessed by the Investigator using the -5-Text Revision (DSM-5-TR) criteria performed at Screening. Current drug use will be allowed if the candidate can produce a negative urine sample (excluding THC) prior to first dose and are free of any signs/symptoms of withdrawal. The candidate will be informed if they have a positive breathalyzer or urine ethanol test.
  2. Participants who are heavy smokers (>20 cigarettes equivalents per day)
  3. Participants who are unable to abstain from smoking for at least 2 hours before and at least 8 hours after study drug administration.
  4. Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  5. Participants with any history of sleep apnea, myasthenia, or glaucoma.
  6. Any condition possibly affecting drug absorption (e.g., gastrectomy) excluding cholecystectomy within 1 year prior to study.
  7. Participants with a positive test for (HIV), surface antigen (HBsAg), or antibody (HCVAb).
  8. Participants with active suicidal ideation or suicidal behavior within 5 years prior to Screening as determined through the use of the Columbia Suicide Severity Rating Scale (C-SSRS) or active ideation identified at Screening or on Day -1.
  9. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or clinically significant laboratory abnormality that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  10. Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product. (Refer to Section 6.8 for additional details).
  11. Herbal supplements and herbal medications must be discontinued at least 14 days prior to the first dose of study medication.
  12. Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives (whichever is longer) prior to screening.
  13. Positive urine drug screen (UDS) for substances of abuse at admission to the Qualification Phase, excluding tetrahydrocannabinol (THC). If a participant presents with a positive UDS (excluding THC) at admission or any visit, the investigator, at his/her discretion, may reschedule a repeat UDS until the UDS is negative (excluding THC) before the participant is permitted to be dosed in any phase of the study.
  14. Participants who are unable to abstain from using THC during the inpatient stays in the Qualification and Treatment Phases of the study.
  15. Has participated in, is currently participating in, or is seeking treatment for substance and/or alcohol related disorders (excluding nicotine and caffeine). If participation in a rehabilitation program was court-mandated as part of a plea agreement, entry may be permissible at the Investigator's discretion.
  16. Has a positive urine ethanol test upon admission to the study center. Positive results may be repeated and/or participants rescheduled at the Investigator's discretion.
  17. Screening sitting BP 145 mm Hg (systolic) or 95 mm Hg (diastolic), following at least 5 minutes of rest. If BP is 145 mm Hg (systolic) or 95 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility. Repeated BP tests should be spaced at least 5 minutes apart.
  18. Baseline (screening) 12 lead that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (e.g., baseline (QTc) interval as determined by the Fridericia method (QTcF) >450 msec (males) or >470 msec (females), complete left bundle branch block [LBBB], signs of an acute or indeterminate-age myocardial infarction, ST T interval changes suggestive of myocardial ischemia, second- or third-degree atrioventricular [AV] block, or serious bradyarrhythmias or tachyarrhythmias). If QTcF exceeds 450 msec (males) or 470 msec (females), or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTcF or QRS values should be used to determine the participant's eligibility. Computer-interpreted ECGs should be overread by an Investigator experienced in reading ECGs before excluding participants.
  19. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed to be clinically significant in the opinion of the investigator:

    • (AST) or alanine aminotransferase (ALT) level 1.5 × (ULN);
    • Total level 1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ULN.
  20. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 56 days prior to dosing.
  21. History of sensitivity to heparin or heparin-induced thrombocytopenia.
  22. Unwilling or unable to comply with the criteria in the Lifestyle considerations section of the protocol.
  23. History of to gabapentin or alprazolam or any of the components in the formulation of the study products.
  24. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Sponsor employees, including their family members, directly involved in the conduct of the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
44 participants (actual)

Study arms

  • Active comparator
    Treatment Phase A

    Drug: Alprazolam (Xanax)

  • Placebo comparator
    Treatment Phase B

    Drug: Placebo

  • Active comparator
    Treatment Phase C

    Drug: Gabapentin (Neurontin® (Registered Trademark))

  • Active comparator
    Treatment Phase D

    Drug: Gabapentin (Neurontin® (Registered Trademark))

06

What researchers measure

Primary outcomes

  1. Bipolar Visual Analog Scale (VAS) for "Drug Liking" Maximum Effect (Emax)

    Drug liking assesses how much a participant likes or dislikes a drug effect at the time the question is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking"

    Time frame: Up to 24 hours after treatments

Secondary outcomes

  1. Bipolar VAS for "Drug Liking" (Time for Emax [TEmax])

    Time after dosing when the maximum effect for Drug Liking VAS is reached

    Time frame: Up to 24 hours after treatments

  2. Bipolar VAS for "Drug Liking" (Area Under the Effect-time Profile From Time 0 to the Time of the Last Quantifiable Effect [AUEClast])

    Area under the effect-time profile from time 0 to the time of the last available data for the "Drug liking" visual analog scale which assesses how much a participant likes or dislikes a drug effect at the time the question ("at this moment, my liking this drug is") is being asked. It is scored using a 100 mm visual analogue scale (VAS), where 0 mm = "Strong Disliking", 50 mm = "Neither Like nor Dislike", and 100 mm = "Strong Liking". The minimum and maximum possible scores are approximately 0 and 2400 if a subject scores 0 mm (strong disliking) and 100 mm (strong liking) respectively at every timepoint up to 24 hours.

    Time frame: Up to 24 hours after treatments (Assessments were made at the following timepoints after each treatment: 0, 0.25, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours)

  3. Unipolar VAS for "High" (Maximum Effect, Emax)

    Maximum effect on the 100 mm visual analog scale for the question "I am feeling high" where 0 = "not at all" and 100 = "extremely"

    Time frame: Up to 24 hours after treatments

  4. Unipolar VAS for "High" (Time for Emax [TEmax])

    Time after dosing when the maximum effect for "High" VAS is reached

    Time frame: Up to 24 hours after treatments

  5. Unipolar VAS for "High" (Area Under the Effect-time Profile From Time 0 to the Time of the Last Quantifiable Effect [AUEClast])

    Area under the effect-time profile from time 0 to the time of the last available data for the "High" visual analog scale which measures on a 100 mm visual analog scale the subject's response to the question "I am feeling high" where 0 = "not at all" and 100 = "extremely". The minimum and maximum possible scores are 0 and approximately 2400 if a subject scores 0 mm (not at all) and 100 mm (extremely) respectively at every timepoint up to 24 hours.

    Time frame: Up to 24 hours after treatments (Assessments were made at the following timepoints after each treatment: 0, 0.25, 0.5,1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24 hours)

  6. Bipolar VAS for "Take Drug Again"

    100 mm visual analog scale for the question "I would take this drug again" where 0 = "definitely not", 50 = "neutral", and 100 = "definitely so".

    Time frame: at 12 and 24 hours after treatments

  7. Bipolar VAS for "Overall Drug Liking"

    100 mm visual analog scale for the question "Overall, my liking for this drug is" where0 = "definitely not", 50 = "neutral", and 100 = "definitely so".

    Time frame: at 12 and 24 hours after treatments

  8. Pharmacokinetics of gabapentin

    Maximum plasma concentration (Cmax), time when the maximum concentration is reached (Tmax), and Area Under the concentration time profile from time 0 to the time of the last quantifiable concentration (AUClast) for gabapentin measured from blood samples

    Time frame: Up to 24 hours after treatments (concentrations were measured at the following timepoints after each treatment for this outcome measure: 0, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12 and 24hours)

07

Study locations

1 site
  • Dr. Vince Clinical Research
    Overland Park, Kansas 66212, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2026 to primary completion in Aug 2026, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 17, 2026
First posted
Aug 21, 2026
StartActual
Jun 18, 2026
Primary completionActual
Aug 31, 2026
CompletionActual
Aug 31, 2026
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07777965
Lead sponsor
Viatris Inc.
Collaborators
Dr. Vince Clinical Research
Responsible party
Sponsor
First posted
Aug 21, 2026
Start date
Jun 18, 2026
Primary completion
Aug 31, 2026
Completion
Aug 31, 2026
Last update
Sep 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alprazolam · Gabapentin

Start the discussion